Definitive Contract 75A50122C00081
Award Date
9/30/22
Potential Completion Date
8/31/32
Potential Value
$74M
Awardee
VIR Biotechnology, Inc.
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost Sharing
Place of Performance
San Francisco, CA 94158, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR) awarded a $63,239,785.00 definitive contract to Arcturus Therapeutics, Inc. for the procurement of a pandemic influenza vaccine (PandFlu) and a quadrivalent seasonal influenza vaccine (QsFlu). This contract is not a set-aside and supports the Arcturus self-amplifying mRNA-based vaccine platform for rapid pandemic influenza response, a key priority under ASPR's Biomedical...
This is a federal contract award to Regeneron Pharmaceuticals Inc., a for-profit manufacturer of pharmaceuticals and therapeutics. The $692,086,314.00 award was made by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency within the U.S. Department of Health and Human Services (HHS). The contract is for the development and production of "novel antibodies against influenza virus, emerging, re-emerging, and pre-emerging pathogens" under an Other...
This is a federal contract award made by the Office of the Assistant Secretary for Preparedness and Response (ASPR), part of the U.S. Department of Health and Human Services (HHS), to Venatorx Pharmaceuticals Inc., a biopharmaceutical company specializing in the discovery and development of novel anti-infective therapeutics. The contract, valued at $147,481,537.00, does not have a set-aside designation and was awarded as a definitive, cost-sharing contract. The work under this contract focuses...
The U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, awarded a $664,774 firm-fixed-price contract to US Biologic, Inc. for the development of a rapid-response oral influenza vaccine. This contract was awarded under a Broad Agency Announcement (BAA) that sought research and development of innovative medical countermeasures. The contract has a completion date of February 29, 2024 and was not set aside for any specific business type. The...
The Department of Health and Human Services' Biomedical Advanced Research and Development Authority awarded a $269,952,453 firm fixed price definitive contract to Global Health Investment Corporation, a nonprofit organization. This contract establishes a public-private partnership through BARDA's other transaction authority to address gaps in pandemic preparedness and response. Specifically, the partnership will foster and accelerate medical countermeasure development using strategic venture...
This is a $38,900,000.00 firm fixed-price definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to Hologic, Inc. to ensure test availability for SARS-CoV-2 after the emergency authorization closes. The purpose is for Hologic to submit an in vitro diagnostic (IVD) assay for SARS-CoV-2, influenza A, influenza B, and respiratory syncytial virus (RSV) by September 30, 2027. This contract was awarded under a Broad Agency Announcement (BAA)...
The Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response (ASPR) awarded a Cost Sharing Definitive Contract to Vaccitech (UK) LIMITED, a For Profit Organization, for the advanced research and development of vaccine candidates to address Chemical, Biological, Radiological, Nuclear (CBRN), pandemic influenza, and emerging infectious disease threats to the U.S. civilian population. The $9,299,269.00 contract, awarded on February 12, 2019, supports...
This is a $749,999.01 firm fixed-price definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency, to Red Queen Therapeutics Inc., a self-certified small disadvantaged business. The contract is for research and development of a rapid response platform for the development of a pan-influenza virus fusion inhibitor for the treatment of influenza virus infections. This contract is not set aside and has an ultimate completion date of...
This is a firm fixed-price delivery order awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency, to MedImmune LLC for $1,800,000.00. The contract is part of the Pandemic Influenza Preparedness and Response 2016-2021 indefinite-delivery, indefinite-quantity (IDIQ) contract vehicle, which is used by ASPR to procure products and services related to pandemic preparedness. The contract has an ultimate completion date of October 31, 2018 and does...
This federal contract award was made by the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR) to Seqirus Inc., a division of the global biotechnology company CSL Seqirus. The $18,890,210.47 fixed-price delivery order is for the acquisition of medical countermeasures for pandemic influenza preparedness and response. The contract is a task order under a larger $13.4 billion Indefinite Delivery Contract (IDC) awarded by HHS...